Molecular analysis of xenograft models of human cancer cachexia - Possibilities for therapeutic intervention

Cancer Genomics and Proteomics

Volumn 4, Issue 3, 2007, Pages 223-232

  Baumgarten, Axel J ^a   Fiebig, Heinz Herbert ^a   Burger, Angelika M ^b,c  

^a CHARLES RIVER LABORATORIES   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c Bressler Research Building ^*  (United States)

Author keywords

Cachexia; COX 2 inhibition; Cytokines; Genomic profiling; Human tumor xenografts; Renal cell cancer

Indexed keywords

CYCLOOXYGENASE 2; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 8; NIMESULIDE; PARATHYROID HORMONE RELATED PROTEIN; PEPTIDES AND PROTEINS; PROSTAGLANDIN E2; PROTEIN DKFZ564111922; ROFECOXIB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA LIGAND SUPERFAMILY PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CACHEXIA; CONTROLLED STUDY; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN GENOME; HYPERCALCEMIA; KIDNEY CANCER; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PATHOGENESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT;

MUS;

EID: 34249679184     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Andreyev HJN, Norman AR, Oates J and Cunningham D: Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignacies? Eur J Cancer 34: 503-509, 1998.
2. Fearon KC and Moses AG: Cancer cachexia. Int J Cardiol 85: 73-81, 2002.
3. Tisdale MJ: Pathogenesis of cancer cachexia. J Support Oncol 1: 159-168, 2003.
4. Muscaritoli M, Bossola M, Aversa Z, Bellantone R and Fanelli FR: Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer 42: 31-41 2006.
5. Dunlop RJ and Campbell CW: Cytokines and advanced cancer. J Pain Symptom Manag 20: 214-232, 2000.
6. Tisdale MJ: Biology of cachexia. J Natl Cancer Inst 89(23): 1763-1773, 1997.
7. Hussey HJ and Tisdale MJ: Effect of the specific cyclooxygenase-2 inhibitor meloxicam on tumor growth and cachexia in a murine model. Int J Cancer 87: 95-100, 2000.
8. Gelin J, Andersson C and Lundholm K: Effects of indomethacin, cytokines, and cyclosporin A on tumor growth and the subsequent development of cancer cachexia. Cancer Res 51: 880-885, 1991.
9. Mulligan HD, Mahony SM, Ross JA and Tisdale MJ: Weight loss in a murine cachexia model is not associated with the cytokines tumour necrosis factor-alpha or interleukin-6. Cancer Lett 65: 239-243, 1992.
10. Burger AM, Leyland-Jones B, Banerjee K, Spyropoulos DD and Seth AK: Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer. Eur J Cancer 41: 1515-1527, 2005.
11. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T and Wallace J: United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). Br J Cancer 77: 1-10, 1998.
12. Fiebig HH, Berger DP, Dengler WA, Wallbrecher E and Winterhalter BR: In: Immunodeficient Mice in Oncology. Fiebig HH, Berger DP (eds.). Contrib Oncol Basel Karger Verlag, pp. 321-351, 1992.
13. Burger AM: Standard TRAP assay. In: Telomeres and Telomerase: Methods in Molecular Biology. Double JA, Thompson MJ (eds.). Vol. 191, chap. 7, The Humana Press Inc, Totowa, NJ-USA, pp. 109-124, 2002.
14. Cahlin C, Körner A, Axelsson H, Wang W, Lundholm K and Svanberg E: Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL-6), IL-12, interferon γ, and tumor necrosis factor α evaluated in gene knockout, tumor-bearing mice on C57 B1 background and eicosanoid-dependent cachexia. Cancer Research 60: 5488-5493, 2000.
15. Dodwell DJ: Malignant bone resorption: cellular and biochemical mechanisms. Ann Oncol 3: 257-267, 1992.
16. Martin-Ventura JL, Ortego M, Esbrit P Hernandes-Presa MA, Ortega L and Egido J: Possible role of parathyroid hormone-related protein as a proinflammatory cytokine in atherosclerosis. Stroke 34: 1783-1789, 2003.
17. Ogata E: Parathyroid hormone-related protein as a potential target of cancer-associated morbidity. Cancer 88: 2909-2911, 2000.
18. Sato K, Onuma E, Yocum RC and Ogata E: Treatment of malignancy-associated hypercalcemia and cachexia with humanized anti-parathyroid hormon-related protein antibody. Seminars in Oncology 30: 167-173, 2003.
19. Lewis MI: Apoptosis as a potential mechanism of mucle cachexia in chronic obdtructive pulmonary disease. Am J Crit Care Med 166: 434-436, 2002.
20. Sharma R and Anker SD: Cytokines, apoptosis and cachexia: the potential for TNF antagonism. Int J Cardiol 85: 161-171, 2002.
21. UniGene Cluster Hs.99899
22. Moser B, Loetscher M, Piali L and Loetscher P: Lymphocyte responses to chemokines. Int Rev Immunol 16: 323-344, 1998.
23. Tisdale MJ: Protein loss in cancer cachexia. Science 289, 2000.
24. Moser B, Loetscher M, Piali L and Loetscher P: Lymphocyte responses to chemokines. Int Rev Immunol 16: 323-344, 1998.
25. Salomon I, Netzer N, Wildbaum G, Schif-Zuck S, Mao G and Karin N: Targeting the funktion of IFN-gamma-inducible protein 10 suppresses ongoing adjuvant arthritis. J Immunol 169: 2685-2693, 2002.
26. Crowl RM and Luk D: Identification of the gene encoding Adlican, a novel protein expressed in human arthritic tissues (http://www.ebi.uniprot.org/entry/ Q9NR99).
27. Argiles JM and Lopez-Soriano FJ: The role of cytokines in cancer cachexia. Med Res Rev 19: 223-248, 1999.